Introduction {#s1}
============

Infectious disease is a major driving force of natural selection on human populations. Such evolutionary pressures can select for genetic variants that confer increased resistance to infectious agents, but may also predispose to specific genetic disorders, as exemplified by *Plasmodium* selection for the sickle-cell trait ([@bib2]). Like sickle-cell disease, chronic kidney disease also affects millions worldwide ([@bib20]), with a disproportionate risk in populations of recent sub-Saharan African ancestry ([@bib44]; [@bib45]; [@bib41]). In African-Americans a large component of this disparity has been attributed to two common genetic variants of *APOL1* (MIM 603743), known as G1 and G2 ([@bib18]; [@bib61]). These variants are closely spaced in the C-terminal domain of *APOL1* but are located on separate haplotypes ([@bib18]) ([Figure 1](#fig1){ref-type="fig"}). Individuals possessing a high-risk G1/G1, G2/G2 or G1/G2 genotype composed of two risk alleles (approximately 13% of African-Americans \[[@bib15]\]), are strongly predisposed to a wide spectrum of chronic kidney disorders that includes focal segmental glomerulosclerosis ([@bib18]; [@bib36]), HIV-associated nephropathy ([@bib36]; [@bib31]) and end-stage renal disease ([@bib18]; [@bib61]; [@bib14]). *APOL1* G1 and G2 are prevalent only in populations of recent African heritage ([@bib18]; [@bib36]), with evidence for a selective sweep within the last 10,000 years ([@bib18]), indicative of strong positive selection. Human African trypanosomiasis (HAT), a deadly parasitic disease endemic to sub-Saharan Africa, has been proposed as the source of this positive selective pressure ([@bib18]). HAT is caused by two tsetse fly-transmitted African trypanosomes, *Trypanosoma brucei rhodesiense* and *T.b. gambiense,* which are responsible for the acute East African form and more chronic West Africa form of the disease, respectively ([@bib32]). Both parasites have been responsible for widespread fatal epidemics in sub-Saharan Africa throughout recorded human history ([@bib54]) suggesting the potential to exert potent selection pressure on the human genome. A heterozygous advantage model has been proposed for *APOL1* G1 and G2 ([@bib18]) in which recessive susceptibility to chronic kidney disease is balanced by dominant resistance to one or both forms of human African trypanosomiasis.10.7554/eLife.25461.003Figure 1.Schematic of G1 and G2 polymorphisms in human apolipoprotein L1.Human apolipoprotein-L1 (APOL1) is a 398-amino acid protein consisting of a cleavable N-terminal signal peptide, a pore-forming domain, a membrane-addressing domain, and a serum resistance-associated (SRA)-interacting domain. The polymorphisms that characterize the G1 and G2 renal risk variants are located in the SRA-interacting domain, the target site for binding of the SRA protein expressed by the human-infective *T.b.rhodesiense* parasite, which results in loss of APOL1 lytic function. The location of the critical binding region (residues 370--392) for this interaction is indicated by a helical graphic. G1 consists of two missense SNPs rs73885319 (p.Ser342Gly) and rs60910145 (p.Ile384Met) while the G2 polymorphism, rs71785313 (p.Asn388_Tyr389del), is found on an alternative *APOL1* haplotype, and represents an in-frame two amino acid deletion.**DOI:** [http://dx.doi.org/10.7554/eLife.25461.003](10.7554/eLife.25461.003)

Prior to the discovery of its association with kidney disease, *APOL1* had already been recognised for encoding the pore-forming serum protein Apolipoprotein L1, which inserts into trypanosome membranes and effectively lyses the *Trypanosoma* species that cause disease in animals ([@bib63]; [@bib49]; [@bib42]; [@bib59]; [@bib64]). However, the two human-infective subspecies have evolved independent mechanisms to resist APOL1-mediated lysis. In *T.b. rhodesiense,* this is the result of an APOL1-binding protein ([@bib68]; [@bib11]) whereas for *T.b. gambiense* the mechanism of APOL1 resistance appears more complex and multifactorial ([@bib9]; [@bib62]; [@bib13]; [@bib33]). It has been hypothesised that *APOL1* G1 and G2 variants could overcome one or more of these resistance mechanisms to protect against HAT. Indeed, previous studies have shown that *APOL1* G2 (and to a lesser extent G1) plasma is lytic to East African *T.b. rhodesiense* parasites *in vitro* ([@bib18]), but not West African *T.b. gambiense* ([@bib18]). Consequently, *T.b. rhodesiense* is considered the most likely candidate for positive selection of both *APOL1* variants in African populations ([@bib18]). Notably, however, the G1 variant appears significantly less effective at killing *T.b. rhodesiense*, and is found at very high frequency in West Africa ([@bib18]; [@bib36]; [@bib34]; [@bib58]), where only *T.b. gambiense* is endemic ([@bib53]).

Furthermore, a class of asymptomatic individuals has been recently identified in *T.b. gambiense* disease foci, who exhibit a long-term *T.b. gambiense-*specific serological response but low or undetectable parasitemia indicative of a latent asymptomatic infection ([@bib35]; [@bib29]; [@bib7]; [@bib25]; [@bib28]; [@bib17]). Parasites from such individuals appear genetically indistinguishable from those of *T.b. gambiense* clinical cases ([@bib30]), suggesting disease outcome may be mediated by, as yet unidentified, host genetic factors. Field studies are therefore warranted to fully evaluate the contribution of variants of the host protein APOL1 to HAT susceptibility.

Here, we present a retrospective association study to test the relationship between *APOL1* G1 and G2 variants and susceptibility to the two different forms of human African trypanosomiasis, *T.b. rhodesiense* in East Africa and *T.b. gambiense* in West Africa. In Uganda, an association analysis was performed between *T.b. rhodesiense*-infected individuals and controls in a major disease focus. In the principal *T.b. gambiense* focus in Guinea, the presence of both clinical patients and asymptomatic individuals permitted a two-stage analysis. Firstly, the association between *APOL1* variants and susceptibility to *T.b. gambiense* infection (infected versus controls), and secondly the association with disease outcome following infection (clinical cases versus asymptomatic carriage). We report that the association of *APOL1* chronic kidney disease variants with HAT susceptibility are markedly different for the two subspecies. As hypothesised, a dominant protective association was detected for the G2 variant against *T.b. rhodesiense* infection. Conversely, we found that the *APOL1* G1 variant was not associated with resistance to *T.b. rhodesiense* infection, but with protective asymptomatic carriage of *T.b. gambiense*. We consider the implications of these strikingly different susceptibilities in the context of human co-evolution with African trypanosomes and the distribution, selection and persistence of these kidney disease risk variants in sub-Saharan Africa.

Results {#s2}
=======

*APOL1* variants and resistance/susceptibility to *T.b. rhodesiense* {#s2-1}
--------------------------------------------------------------------

To test the heterozygous advantage hypothesis proposed for these *APOL1* variants against *T.b. rhodesiense* infection ([@bib18]), 180 controls and 184 clinically confirmed *T.b. rhodesiense* patients from a principle disease focus in central-eastern Uganda were genotyped for G1 and G2 polymorphisms. The G1 haplotype comprises of two non-synonymous substitutions, rs73885319 and rs60910145 situated just 128 bp apart and in near-perfect linkage disequilibrium ([@bib18]; [@bib36]). In this study, as reported by others ([@bib36]; [@bib6]), a small number of individuals were identified with only a partial G1 haplotype (the kidney disease risk genotype at one of the G1 polymorphism positions but the non-risk genotype at the other) and were excluded from the G1 haplotype association analysis. The second chronic kidney disease risk variant, G2 (rs71785313), is found on an alternative haplotype and represents a six base pair in-frame deletion.

Comparing genotype frequencies in confirmed *T.b. rhodesiense*-infected individuals with uninfected controls found no association between the G1 haplotype and *T.b. rhodesiense* infection (p=0.50; [Table 1](#tbl1){ref-type="table"}). In contrast, we observed a significant dominant protective association for the G2 variant, with an odds ratio of 0.20 (95% CI: 0.07 to 0.48, p=0.0001; [Table 1](#tbl1){ref-type="table"}). This indicates a five-fold reduced susceptibility to *T.b. rhodesiense* infection for individuals that possess a single copy of the G2 variant, compatible with a model of heterozygous protection.10.7554/eLife.25461.004Table 1.Association between *APOL1* kidney disease risk variants and *T.b*. *rhodesiense* infection**DOI:** [http://dx.doi.org/10.7554/eLife.25461.004](10.7554/eLife.25461.004)10.7554/eLife.25461.005Table 1---source data 1.*APOL1* genotype data for *T.b. rhodesiense-*infected individuals and controls^\*^Individuals excluded from the *APOL1* G1 association analysis. *T.b.r: T.b. rhodesiense*, G0: genotype compatible with the non-risk G0 allele for both rs73885319 and rs60910145, G1: genotype compatible with the G1 CKD risk allele for both rs73885319 and rs60910145, G1^M^: genotype compatible with the G1 CKD risk allele for rs60910145 and the non-risk G0 allele for rs73885319, G1^G^: genotype compatible with the G1 CKD risk allele for rs73885319 and the non-risk G0 allele for rs60910145, G2: genotype compatible with the G2 CKD risk allele for rs71785313.**DOI:** [http://dx.doi.org/10.7554/eLife.25461.005](10.7554/eLife.25461.005)10.7554/eLife.25461.006Table 1---source data 2.Association between individual *APOL1* G1 kidney disease risk variants and *T.b*. *rhodesiense* infection Two-tailed Fisher\'s exact test with mid-P method using a dominant genetic model (carriage of 1 or 2 copies of the designated *APOL1* SNP).CKD: chronic kidney disease, *T.b.r: T.b. rhodesiense*, OR: odds ratio, CI: confidence interval. Raw data for [Table 1---source data 2](#SD2-data){ref-type="supplementary-material"} can be found in [Table 1---source data 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.25461.006](10.7554/eLife.25461.006)Dominant model - Infection***APOL1* haplotype*T.b.r* infectedControlAssociation analysis^\*^**\
***T.b.r* infected/Control**Number%Number%OR \[95% CI\]*P*G0 Ancestral Haplotype\
rs73885319 (A) + rs60910145 (T) + rs71785313 (TTATAA)G0184100.017999.4N.C0.49Non-G000.010.6Total184100.0180100.0G1 Haplotype^†^\
rs73885319 (A\>G) + rs60910145 (T\>G)G194.9126.70.73 \[0.29 to 1.79\]0.50Non-G117395.116893.3Total182100.0180100.0G2 Haplotype\
rs71785313 (TTATAA\>del6)\
G263.32614.40.20 \[0.07 to 0.48\]0.0001Non-G217896.715485.6Total184100.0180100.0[^2][^3]

*APOL1* variants and resistance/susceptibility to *T.b. gambiense* {#s2-2}
------------------------------------------------------------------

### Infection {#s2-2-1}

To evaluate the impact of these polymorphisms in driving resistance/susceptibility to *T.b. gambiense* infection, G1 and G2 polymorphisms were genotyped in 227 *T.b. gambiense*-infected individuals and 104 controls from the mangrove focus in Guinea. When compared to control genotype frequencies, neither variant demonstrated an association with susceptibility to *T.b. gambiense* infection (p=0.47 \[G1\], p=0.50 \[G2\], [Table 2](#tbl2){ref-type="table"}).10.7554/eLife.25461.007Table 2.Association between kidney disease risk variants and *T.b. gambiense* infection**DOI:** [http://dx.doi.org/10.7554/eLife.25461.007](10.7554/eLife.25461.007)10.7554/eLife.25461.008Table 2---source data 1.*APOL1* genotype data for *T.b. gambiense-*infected individuals and controls^\*^Individuals excluded from the *APOL1* G1 association analysis. *T.b.g: T.b. gambiense*, G0: genotype compatible with the non-risk G0 allele for both rs73885319 and rs60910145, G1: genotype compatible with the G1 CKD risk allele for both rs73885319 and rs60910145, G1^M^: genotype compatible with the G1 CKD risk allele for rs60910145 and the non-risk G0 allele for rs73885319, G1^G^: genotype compatible with the G1 CKD risk allele for rs73885319 and the non-risk G0 allele for rs60910145, G2: genotype compatible with the G2 CKD risk allele for rs71785313.**DOI:** [http://dx.doi.org/10.7554/eLife.25461.008](10.7554/eLife.25461.008)10.7554/eLife.25461.009Table 2---source data 2.Association between individual *APOL1* G1 kidney disease risk variants and *T.b. gambiense* infection Two-tailed Fisher\'s exact test with mid-P method using a dominant genetic model (carriage of 1 or 2 copies of the designated *APOL1* SNP).CKD: chronic kidney disease, *T.b.g: T.b. gambiense*, OR: odds ratio, CI: confidence interval. Raw data for [Table 2---source data 2](#SD4-data){ref-type="supplementary-material"} can be found in [Table 2---source data 1](#SD3-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.25461.009](10.7554/eLife.25461.009)**Dominant model - Infection**APOL1 haplotype*T.b.g* infectedControlAssociation analysis^\* ^\
*T.b.g* infected/ControlNumber%Number%OR \[95% CI\]*P*G0 Ancestral Haplotype\
rs73885319 (A) + rs60910145 (T) + rs71785313 (TTATAA)G019686.38985.61.07 \[0.54 to 2.06\]0.84Non-G03113.71514.4Total227100.0104100.0G1 Haplotype^†^\
rs73885319 (A\>G) + rs60910145 (T\>G)G17333.53029.41.21 \[0.73 to 2.03\]0.47Non-G114566.57270.6Total218100.0102100.0G2 Haplotype\
rs71785313 (TTATAA\>del6)G26830.03533.70.84 \[0.51 to 1.40\]0.50Non-G215970.06966.3Total227100.0104100.0[^4][^5]

### Disease outcome {#s2-2-2}

Infection with *T.b. gambiense* is associated with distinct clinical outcomes. *T.b. gambiense-*infected individuals can be subdivided into clinical stage trypanosomiasis patients who are serology and microscopy positive for trypanosomiasis (n = 167), and latent carriers (n = 60), who are defined as strongly serology positive, but asymptomatic and aparasitemic by microscopic examination for a period of at least two years. When comparing clinical cases and latent carriers, significant opposing associations were observed for the two *APOL1* variants with *T.b. gambiense* infection outcome ([Table 3](#tbl3){ref-type="table"}). There was an association between the G1 variant and dominant protection against developing clinical stage trypanosomiasis (OR = 0.33, 95% CI: 0.17--0.62; p=0.0005). This indicates that *T.b. gambiense*-infected individuals possessing a copy of the G1 *APOL1* variant were three-fold more likely to be latent asymptomatic carriers of *T.b. gambiense*. In contrast, the G2 variant was associated with a three-fold increased susceptibility to clinical stage trypanosomiasis (OR = 3.08, 95% CI: 1.45--7.06, p=0.0025), consistent with a risk of faster disease progression. This association was strengthened still further (OR = 5.87, 95% CI: 2.16--20.01; p=0.0001) when individuals with a potentially antagonistic compound heterozygous (G1/G2) genotype were excluded from the analysis ([Table 4](#tbl4){ref-type="table"}).10.7554/eLife.25461.010Table 3.Association between kidney disease risk variants and *T.b. gambiense* infection outcome**DOI:** [http://dx.doi.org/10.7554/eLife.25461.010](10.7554/eLife.25461.010)10.7554/eLife.25461.011Table 3---source data 1.*APOL1* genotype data for *T.b. gambiense* clinical stage trypanosomiasis patients and latent carriers^\*^Individuals excluded from the *APOL1* G1 association analysis. *T.b.g: T.b. gambiense*, G0: genotype compatible with the non-risk G0 allele for both rs73885319 and rs60910145, G1: genotype compatible with the G1 CKD risk allele for both rs73885319 and rs60910145, G1^M^: genotype compatible with the G1 CKD risk allele for rs60910145 and the non-risk G0 allele for rs73885319, G1^G^: genotype compatible with the G1 CKD risk allele for rs73885319 and the non-risk G0 allele for rs60910145, G2: genotype compatible with the G2 CKD risk allele for rs71785313.**DOI:** [http://dx.doi.org/10.7554/eLife.25461.011](10.7554/eLife.25461.011)10.7554/eLife.25461.012Table 3---source data 2.Association between individual *APOL1* G1 kidney disease risk variants and *T.b. gambiense* infection outcome Two-tailed Fisher\'s exact test with mid-P method using a dominant genetic model (carriage of 1 or 2 copies of the designated *APOL1* SNP).CKD: chronic kidney disease, *T.b.g: T.b. gambiense*, OR: odds ratio, CI: confidence interval. Raw data for [Table 3---source data 2](#SD6-data){ref-type="supplementary-material"} can be found in [Table 3---source data 1](#SD5-data){ref-type="supplementary-material"}**DOI:** [http://dx.doi.org/10.7554/eLife.25461.012](10.7554/eLife.25461.012)**Dominant model -- infection outcome*APOL1* haplotype*T.b.g* Disease*T.b.g* CarriageAssociation analysis^\*^**\
***T.b.g* Disease/Carriage**Number%Number%OR \[95% CI\]*P*G0 Ancestral Haplotype\
rs73885319 (A) + rs60910145 (T) + rs71785313 (TTATAA)G014486.25286.70.96 \[0.38 to 2.25\]0.95Non-G02313.8813.3Total167100.060100.0G1 Haplotype^† ^\
rs73885319 (A\>G) + rs60910145 (T\>G)G14326.73052.60.33 \[0.17 to 0.62\]0.0005Non-G111873.32747.4Total161100.057100.0G2 Haplotype\
rs71785313 (TTATAA\>del6)G25935.3915.03.08 \[1.45 to 7.06\]0.0025Non-G210864.75185.0Total167100.060100.0[^6][^7]10.7554/eLife.25461.013Table 4.Conditional association between kidney disease risk variants and *T.b. gambiense* infection outcome excluding compound heterozygotes**DOI:** [http://dx.doi.org/10.7554/eLife.25461.013](10.7554/eLife.25461.013)10.7554/eLife.25461.014Table 4---source data 1.*APOL1* genotype data for *T.b. gambiense* clinical stage trypanosomiasis patients and latent carriers, excluding compound heterozygotes^\*^Individuals excluded from the *APOL1* G1 association analysis. *T.b.g: T.b. gambiense*, G0: genotype compatible with the non-risk G0 allele for both rs73885319 and rs60910145, G1: genotype compatible with the G1 CKD risk allele for both rs73885319 and rs60910145, G1^M^: genotype compatible with the G1 CKD risk allele for rs60910145 and the non-risk G0 allele for rs73885319, G1^G^: genotype compatible with the G1 CKD risk allele for rs73885319 and the non-risk G0 allele for rs60910145, G2: genotype compatible with the G2 CKD risk allele for rs71785313.**DOI:** [http://dx.doi.org/10.7554/eLife.25461.014](10.7554/eLife.25461.014)10.7554/eLife.25461.015Table 4---source data 2.Association between individual *APOL1* G1 kidney disease risk variants and *T.b. gambiense* infection outcome, excluding compound heterozygotes Two-tailed Fisher\'s exact test with mid-P method using a dominant genetic model (carriage of 1 or 2 copies of the designated *APOL1* SNP).Individuals with a compound heterozygote genotype (G1/G2) were excluded from the analysis. CKD: chronic kidney disease, *T.b.g: T.b. gambiense*, OR: odds ratio, CI: confidence interval. Raw data for [Table 4---source data 2](#SD8-data){ref-type="supplementary-material"} can be found in [Table 4---source data 1](#SD7-data){ref-type="supplementary-material"}**DOI:** [http://dx.doi.org/10.7554/eLife.25461.015](10.7554/eLife.25461.015)**Dominant model -- infection outcome*APOL1* haplotype*T.b.g* Disease*T.b.g* CarriageAssociation analysis^\*^**\
***T.b.g* Disease/Carriage**Number%Number%OR \[95% CI\]*P*G1 Haplotype^†,‡ ^\
rs73885319 (A\>G) + rs60910145 (T\>G)G13623.42548.10.33 \[0.17 to 0.64\]0.0012Non-G111876.62751.9Total154100.052100.0G2 Haplotype^‡ ^\
rs71785313 (TTATAA\>del6)G25031.647.35.87 \[2.16 to 20.01\]0.0001Non-G210868.45192.7Total158100.055100.0[^8][^9][^10]

Together these associations, summarised in [Figure 2A](#fig2){ref-type="fig"}, indicate that the G1 and G2 *APOL1* variants exhibit distinct subspecies-specific susceptibility profiles in relation to the two causative agents of human African trypanosomiasis. The G1 variant is associated with asymptomatic carriage of *T.b. gambiense*, but the predicted protection against *T.b. rhodesiense* infection ([@bib18]) was not detected. For the G2 variant, opposing dominant associations were observed with the two different subspecies. This association is protective against *T.b. rhodesiense* infection, but with increased susceptibility to a more severe disease outcome for *T.b. gambiense*.10.7554/eLife.25461.016Figure 2.The geographical distribution of human African trypanosomiasis and *APOL1* G1 and G2 allele frequencies across sub-Saharan Africa.(**A**) The risk model for chronic kidney disease, *T.b. rhodesiense* infection, and *T.b. gambiense* disease outcome are summarized for the ancestral G0 *APOL1* variant and heterozygous and homozygous carriers of the G1 and G2 variants. The direction of the risk association is indicated by arrow orientation and box colour: orange (increased risk), blue (reduced risk) and grey (no association). (**B**) WHO defines 36 countries as endemic for HAT, caused by *T.b. gambiense* in West Africa (blue) and *T.b. rhodesiense* in East Africa (green). Uganda is the only country endemic for both subspecies, although their distribution does not currently overlap (red). (**C**) Spatial frequency map of the *APOL1* G1 variant. (**D**) Spatial frequency map of the *APOL1* G2 variant. Spatial frequency maps were generated from merged published genotype data available for 40 populations (5287 individuals) in 21 countries ([Figure 2---source data 1](#SD9-data){ref-type="supplementary-material"}). Colour gradients illustrating predicted allele frequencies across Africa were extrapolated from available data using the Kriging algorithm in Surfer software version 8. The approximate locations of data points are indicated by filled black circles, a filled red triangle (Guinea study), or an inverted filled red triangle (Uganda study) next to the relative allele frequency, in percentage.**DOI:** [http://dx.doi.org/10.7554/eLife.25461.016](10.7554/eLife.25461.016)10.7554/eLife.25461.017Figure 2---source data 1.Frequency of *APOL1* G1 and G2 variants in African populations.Where data for G1 allele frequency were unavailable, data are inferred from rs73885319 only. N/A: Data not available, CEPH-HGDP: Centre d'Etude du Polymorphisme Humain - Human Genome Diversity Panel, TCGA-UCL: The Centre for Genetic Anthropology at University College London.**DOI:** [http://dx.doi.org/10.7554/eLife.25461.017](10.7554/eLife.25461.017)

Geographical distribution of *APOL1* G1 and G2 variants {#s2-3}
-------------------------------------------------------

To visualize the geographic distribution of *APOL1* variants in relation to HAT endemicity ([Figure 2B](#fig2){ref-type="fig"}), data generated by this study were merged with previously reported allele frequencies for 38 other sub-Saharan African populations, to produce a cohort of 5287 genotyped samples. Frequency distributions for G1 and G2 were transformed into geographical contour maps using the Kriging algorithm for data interpolation ([Figure 2C and D](#fig2){ref-type="fig"}). The allele frequencies from the Ugandan population and the mangrove foci in Guinea appear consistent with the general geographical distribution pattern for these variants in sub-Saharan Africa. Both variants are reported at higher prevalence in *T.b. gambiense* endemic West Africa, particularly G1, which reaches frequencies as high as 49% in the Ibo ([@bib58]) and Esan ([@bib1]) tribes of Nigeria, decreasing to complete absence in Northeast Africa ([@bib61]; [@bib6]). Allele frequency is moderately inversely correlated with longitude for both G1 (Pearson correlation: *r* = −0.526, p=2.0 × 10^−4^, *N* = 40) and G2 (*r* = −0.593, p=5.7 × 10^−5^, *N* = 37) but not latitude (G1, p=0.33, G2, p=0.30), indicating a significant decreasing relative frequency for both *APOL1* variants from West to East across the continent.

Discussion {#s3}
==========

Here, we report the first association study between *APOL1* G1 and G2 kidney disease risk variants and *T.b. rhodesiense* and *T.b. gambiense*, revealing a more complex relationship with human African trypanosomiasis susceptibility than was originally predicted. The implications of these findings in relation to each of the human-infective parasite subspecies are considered in turn.

The zoonotic *T.b. rhodesiense* parasite has been responsible for a number of severe HAT outbreaks in recent human history in East Africa that have claimed hundreds of thousands of lives ([@bib24]; [@bib16]). Our data indicate that the *APOL1* G2 variant was strongly associated with protection against *T.b. rhodesiense* infection in a Ugandan disease focus. The observed five-fold reduced susceptibility for individuals possessing a single copy of the *APOL1* G2 variant is consistent with laboratory studies reporting in vitro lysis of *T.b. rhodesiense* for APOL1 G2 plasma and recombinant protein ([@bib18]), and increased survival of *APOL1* G2 transgenic mice in a *T.b. rhodesiense* infection model ([@bib58]). *T.b. rhodesiense* parasites are defined by the potential to express the serum-resistance-associated (SRA) protein ([@bib68]; [@bib12]) which binds to ancestral APOL1 (G0), inhibiting its formation of lethal pores in trypanosome membranes ([@bib63]; [@bib49]; [@bib42]; [@bib59]; [@bib64]). The two-amino acid deletion that characterises the G2 haplotype (rs71785313, \[p.N388_Y389del\]), is situated within a C-terminal region of APOL1 demonstrated to be essential for SRA binding ([@bib38]) (residues 370--392; [Figure 1](#fig1){ref-type="fig"}). Studies indicate that G2 shifts the position of a critical lysine residue within the binding region that virtually abolishes the interaction with SRA ([@bib18]; [@bib58]). This implicates evasion of the SRA virulence protein as the probable mechanism by which G2 restores APOL1 lytic function and protects the host against *T.b. rhodesiense* infection. The results of this case-control study add substantial support to the proposed heterozygous advantage model of dominant protection against *T.b. rhodesiense* infection for this recessive kidney disease risk variant.

For the G1 variant, no protective association against *T.b. rhodesiense* infection was detected. This finding is somewhat at odds with the reported moderate in vitro *T.b. rhodesiense* lytic activity for G1 donor plasma and recombinant protein ([@bib18]), and delayed parasitemia in an *APOL1* G1 mouse model ([@bib58]). Notably however, the trypanolytic effect for G1 in both studies was significantly inferior to the G2 variant by up to several orders of magnitude. The G1 haplotype is composed of two closely positioned missense mutations (rs73885319; \[p.S342G\] and rs60910145; \[p.I384M\], [Figure 1](#fig1){ref-type="fig"}), of which the latter is also located in the crucial SRA-binding region. However, the rs60910145 point mutation results in an isoleucine to methionine substitution that only slightly weakens SRA-APOL1 interaction ([@bib18]) and this substitution alone did not extend survival in a mouse model ([@bib58]). Together these data suggest that the G1 variant is not able to confer substantial protection from *T.b. rhodesiense* infection. However, our data do not preclude an effect of G1 on the time course or severity of *T.b. rhodesiense* disease. Additionally, for both the G1 variant and the small number of G2-possessing individuals that were infected with *T.b. rhodesiense* it is possible that dosage effects or inactivating mutations may be present which have abrogated the trypanolytic ability of these *APOL1* variants. No stop codons or mutual non-synonymous variants were observed within the exomes of these individuals during sequence verification of the APOL1 G1 and G2 genotypes ([Supplementary file 1](#SD10-data){ref-type="supplementary-material"}), but this possibility cannot be definitively excluded.

In contrast to *T.b. rhodesiense*, *T.b. gambiense* primarily infects humans, and is the pathogen responsible for the majority of human disease ([@bib53]) and significant and widespread epidemics of a slower progressing form of sleeping sickness in Central and West Africa. No lytic ability for either *APOL1* variant was reported against *T.b. gambiense* tested by in vitro assays with donor plasma or recombinant protein ([@bib18]). Consistent with this observation, in the Guinea focus neither variant demonstrated a resistance association with *T.b. gambiense* infection. Instead, as summarized in [Figure 2A](#fig2){ref-type="fig"}, contrasting associations were observed with infection outcome. *APOL1* G1 was associated with a predisposition to latent asymptomatic carriage, while individuals possessing the G2 variant were more likely to progress to clinical disease. The association between *APOL1* variants and infection outcome for *T.b. gambiense* implicates this molecule as a critical modulating factor in disease control. APOL1 is a high-density lipoprotein-associated serum protein, the expression of which is up-regulated by pro-inflammatory stimuli including IFN-γ ([@bib52]) and TNF-α ([@bib43]). In accordance with this, *APOL1* expression is demonstrably increased during *T.b. gambiense* infection ([@bib26]). However, no association has been observed between *APOL1* expression levels and blood parasite density or clinical outcome of *T.b. gambiense* infection ([@bib26]). Instead, the results of our study indicate that particular *APOL1* variants, rather than modulation of global APOL1 protein level, contribute to differential susceptibility to disease. How these variants influence *T.b. gambiense* is less perceptible than for *T.b. rhodesiense*. The mechanism of *T.b. gambiense* APOL1 resistance does not involve SRA, but three independent contributing components have been implicated: a sub-species-specific protein, TgsGP ([@bib9]; [@bib62]), which alters trypanosome membrane rigidity ([@bib62]); reduced uptake of APOL1 ([@bib13] ; [@bib33]); and proposed faster degradation of APOL1 within the endocytic system of the parasite ([@bib62]; [@bib3]). It is possible that alterations to the APOL1 molecule conferred by G1 and G2 polymorphisms affects one or more of these processes with opposing downstream consequences. Furthermore, the strengthened risk association of G2 with clinical disease when individuals who possess both haplotypes (G1/G2 compound heterozygotes) were excluded indicates a potential dominance for the protective G1 haplotype that might be able to mitigate the disease progressive effects of the G2 variant.

Despite its critical function in human innate resistance to most trypanosomes, the role of APOL1 in *T.b. gambiense* disease progression appears complex. Contrasting inflammatory cytokine profiles reported between individuals with clinical stage disease and latent carriers ([@bib27]) suggests that an intricate multi-gene interplay between host immune factors, APOL1, and the parasite ultimately determines disease outcome for this subspecies.

For the G1 variant, the relationship with *T.b. gambiense* appears more akin to the well- established association between *Plasmodium* and the sickle haemoglobin S (*HbS*) polymorphism ([@bib2]). In this classic example of heterozygous advantage, the heterozygous *HbS* genotype does not protect from *Plasmodium* infection per se but reduces the risk of severe malaria once infected ([@bib2]; [@bib56]). This advantage has selected and maintained prevalence of the *HbS* polymorphism in malaria-endemic sub-Saharan Africa, despite the high penetrance of life-threatening sickle cell disease in homozygotes ([@bib2]; [@bib47]). In *T.b. gambiense*, possession of a G1 allele is associated with the capacity to sustain the asymptomatic latent period of what is normally a fatal disease. This moderation of disease severity could plausibly confer greater survival and reproductive opportunities for individuals possessing the G1 variant than for their G0- or G2-carrying counterparts, who typically progress more rapidly to severe disease (G2 \> G0 \> G1). Such a selection advantage may explain the high allele frequency of G1 recorded in *T.b. gambiense*-endemic West Africa (up to 49% ([@bib58]; [@bib1]);[Figure 2C](#fig2){ref-type="fig"}), which in some populations exceeds even the maximum global *HbS* alleles frequencies ([@bib47]). This is consistent with a strong positive selective force on G1 ([@bib18]), and conceivably, a less powerful opposing deleterious pressure from kidney disease in homozygotes, which is typically of late onset, and incompletely penetrant ([@bib37]).

Population genetics studies of *T. brucei* indicates that both human-infective sub-species likely arose independently and relatively recently from the animal pathogen *T.b. brucei* ([@bib55]; [@bib19]; [@bib4]; [@bib65]). Molecular clock analysis dates the emergence of *T.b. gambiense* as a human pathogen in West Africa from a single progenitor approximately 1,000--10,000 years ago ([@bib65]). During this time a pivotal lifestyle transition was occurring with the development of agriculture and larger, more densely populated permanent settlements that provided favorable conditions for the emergence of many animal-derived human pathogens ([@bib23]; [@bib66]). This also coincides with the timeline for a robust selective sweep on G1 detected in the Nigerian Yoruba population ([@bib18]), at the geographical hotspot for this allele ([Figure 2C](#fig2){ref-type="fig"}) in West Africa. A plausible scenario is that within the last 10,000 years an animal-infective *T.b. brucei* predecessor of *T.b. gambiense* evolved the essential human serum resistance gene *TgsGP* ([@bib9]), facilitating its transmission to humans in the ancestral Bantu population of the Nigeria-Cameroon region. Over time, as *T.b. gambiense* has undergone progressive adaptation into a predominantly human pathogen ([@bib66]), selection for the human *APOL1* G1 variant may have occurred in turn, which was able to mitigate the lethal progression of disease and promote long-term asymptomatic carriage. The *T.b. gambiense*-protective *APOL1* G1 haplotype could then have spread with human migration and introgression into other sub-Saharan populations during the Bantu expansions ([@bib60]), or along commercial routes within the last 4000 years, to reach its current distribution across sub-Saharan Africa ([Figure 2C](#fig2){ref-type="fig"}).

For *APOL1* G2, the increased risk of clinical *T.b. gambiense* disease contrasts with the strong protective association observed for this variant against *T.b. rhodesiense*. Puzzlingly, as for G1, some of the highest frequencies of G2 are also found in *T.b. gambiense-*endemic West Africa ([Figure 2D](#fig2){ref-type="fig"}), raising speculation about the evolutionary history of these two variants. Studies of genetic diversity at the *APOL1* locus are consistent with a older (2,000--7,000 years), less intensively selected allele ([@bib18]; [@bib48]) for G2, and a more recent, rapid sweep for the G1 allele in West Africa ([@bib18]; [@bib48]; [@bib39]). One possible interpretation of the available data is that *T.b. rhodesiense* preceded *T.b. gambiense* in West Africa and was responsible for driving positive selection of the G2 variant in the Nigeria-Cameroon region. Rising frequencies of this protective variant (or other unrelated epidemiological factors) could have then forced an eastward shift in *T.b. rhodesiense* endemicity to an approximation of its current distribution in East and Southern Africa. Subsequently, when *T.b. gambiense* emerged in West Africa, the relative fitness of the *APOL1* G2 allele in the exposed population would have been diminished, providing an opportunity for the robust selective sweep of an alternate *APOL1* variant, G1, which was able to reduce the disease severity of this new pathogen.

While this is an attractive theory, there is little epidemiological support for a shift in the endemicity of *T.b. rhodesiense*, which has only been detected in East Africa and has no recorded history in West Africa ([@bib19]; [@bib50]; [@bib5]; [@bib46]). Moreover, isolates of *T.b. rhodesiense* from across East Africa show a strong genetic relationship with sympatric *T.b. brucei* strains, compatible with a predominantly East African origin ([@bib4]; [@bib21]; [@bib40]). An alternative model is that selection in favour of the G2 variant may have originated from a different source in West Africa, and it is only more recently, as the G2 variant spread eastwards with the Bantu expansion ([@bib60]), that it has fortuitously proved advantageous against *T.b. rhodesiense*. Indeed, beyond its proven capacity for trypanolysis, APOL1 was shown to limit *Leishmania major* infections in mice ([@bib51]) and suppress HIV-replication in macrophages ([@bib57]), hinting at a much broader role for APOL1 in innate immunity to infectious disease.

The association between *APOL1* chronic kidney disease risk variants and human African trypanosomiasis reveals a more complex picture of selection and human evolution than was originally hypothesized. Despite their close genetic proximity *APOL1* G1 and G2 polymorphisms confer very different, and even opposing, dominant associations with human African trypanosomiasis susceptibility, yet appear convergent in their deleterious recessive contribution to kidney pathology. While the origins of the G2 allele remain speculative, a model of dominant protection against *T.b. rhodesiense* infection is supported. For G1, the strong West African allele distribution bias and evidence for recent, rapid, positive selection, suggest an alternative evolutionary ancestry for this allele, which we propose involves protection from the lethal consequences of the *T.b. gambiense* parasite.

Materials and methods {#s4}
=====================

Ethics statement {#s4-1}
----------------

Participants were identified through healthcare providers, community engagement and active field surveillance in association with the national control programmes. Written informed consent for sample collection, analysis and publication of anonymised data was obtained from all participants by trained local healthcare workers. Subjects or their legal guardian gave consent as a signature or a thumbprint after receiving standardised information in English, French or their local language, as preferred, and were free to withdraw from the study at any time. Efforts were made to ensure the engagement of all local stake holders and approval was obtained from local leaders in each study area where appropriate. Ethical approvals for the study were obtained from within the TrypanoGEN Project following H3Africa Consortium guidelines for informed consent ([@bib22]), from Comité Consultatif de Déontologie et d'Ethique (CCDE) at the Institut de recherche pour le développement (IRD; 10/06/2013) for the Guinea study, and from the Uganda National Council for Science and Technology (UNCST; 21/03/2013) for the Uganda study. Research procedures were also approved by the University of Glasgow MVLS Ethics Committee for Non-Clinical Research Involving Human Subjects (Reference no. 200120043).

Sample collection {#s4-2}
-----------------

### Uganda {#s4-2-1}

A *T.b. rhodesiense* cohort of 184 blood samples was collected from patients presenting to local hospitals during an epidemic in the neighbouring districts of Soroti and Kaberamaido in Central Eastern Uganda, along with 180 controls, between 2002 and 2012. The majority of the population is from the Kumam ethnic group. In all cases, *T.b. rhodesiense* infection was confirmed by microscopic detection of trypanosomes in wet blood films, Giemsa stained thick blood films or in the buffy coat fraction after microhaematocrit centrifugation. Blood was collected by venepuncture from consenting participants, and preserved as blood spots on FTA filter cards (Whatman, NJ, USA) with air-drying. For PCR amplification, discs of 2 mm diameter were cut from each blood spot using a Harris Micro-punch (Whatman) and prepared according to the instructions provided by the manufacturer.

### Guinea {#s4-2-2}

Samples were collected from a group of three closely positioned active *T.b. gambiense* HAT foci (Dubreka, Boffa and Forecariah) located in the mangrove area of coastal Guinea ([@bib8]). The majority of the population is from the Soussou ethnic group. All subjects included in this study were identified during medical surveys performed between 2007 and 2011 by the National Control Program according to standard procedures described elsewhere ([@bib25]). For each study participant, 100 µL of plasma and 500 µL of buffy coat were taken. All samples were frozen in the field at −20°C. The highly specific *T. b. gambiense* immune trypanolysis (TL) test was performed on plasma samples as previously described ([@bib28]). We included 331 individuals in three phenotypic categories: (i) HAT patients (n = 167): card agglutination test for trypanosomiasis (CATT) positive and trypanosomes detected by the mini Anion Exchange Centrifugation technique (mAECT) followed by microscopy and / or examination of cervical lymph node aspirates by microscopy when adenopathies were present, (ii) Latent carriers (n = 60) CATT plasma titre 1/8 or higher; TL positive, no trypanosomes detected by mean of mAECT and / or examination of cervical lymph node aspirates during a two-year follow-up; (iii) Uninfected endemic controls (n = 104), CATT negative, TL negative, mAECT negative. DNA was extracted from blood collected in the field with the DNeasy Tissue kit (Qiagen, Germany) according to the instructions provided by the manufacturer.

*APOL1* genotyping {#s4-3}
------------------

### Uganda {#s4-3-1}

The *APOL1* genotype of each individual at the G1 and G2 loci was determined using PCR--restriction fragment length polymorphism (RFLP) analysis. G1 comprises two non-synonymous substitutions, rs73885319 (c.1024A\>G \[p.Ser342Gly\]) and rs60910145 (c.1152T\>G \[p.Ile384Met\]) in near-perfect linkage disequilibrium. The second variant, G2, is found on an alternative haplotype and represents a two amino acid in-frame deletion (c.1164_1169del \[p.Asn388_Tyr389del\]). Prepared FTA card discs were used as template in a PCR amplifying a 458 bp product containing the three known variant sites (primers: *APOL1* F1, 5′- AGACGAGCCAGAGCCAATCTTC-3′ and *APOL1*\_R2, 5′- CACCATTGCACTCCAACTTGGC −3′). PCR reactions were prepared in a volume of 25 µL using conditions previously described ([@bib10]) with a final primer concentration of 10 µM and 1 unit of Taq polymerase (ThermoFisher Scientific, MA, USA). Amplification was performed using 35 cycles of 95°C for 50 s, 67°C for 50 s, and 70°C for 1 min. Following PCR amplification, an independent RFLP assay was performed for each of the three polymorphisms. For SNP rs73885319 (G1^S342G^), the A\>G substitution results in the loss of a HindIII site, for SNP rs60910145 (G1^I384M^) the T\>G substitution creates an NspI site, and for rs71785313, the G2 6 bp deletion results in the loss of an MluCI site. For each reaction, 2 µL of PCR product was digested with 10 units of enzyme and the products separated by electrophoresis on a 2% agarose gel. Data for each SNP (rs73885319, rs60910145, and rs71785313) were combined to generate the *APOL1* genotype for each individual. All individuals that were identified as containing G1 or G2 polymorphisms by RFLP, along with a similar number of randomly selected G0 homozygous individuals were verified by PCR amplification and Sanger sequencing (MWG-Biotech AG, Germany) of *APOL1* protein coding exons 3--7. Sequences were evaluated using CLC genomics software (RRID:[SCR_011853](https://scicrunch.org/resolver/SCR_011853)) for genetic variants relative to NCBI Genome reference build 38.7 (RRID:[SCR_006553](https://scicrunch.org/resolver/SCR_006553); [Supplementary file 1](#SD10-data){ref-type="supplementary-material"}). Details of the PCR and sequencing primers are provided in [Supplementary file 2](#SD11-data){ref-type="supplementary-material"}.

### Guinea {#s4-3-2}

The G1^S342G^ (rs73885319) polymorphism was detected by PCR-RFLP. PCR was carried out in a total volume of 30 µL containing 100 ng of DNA, 10 mM of dNTP, 10 µM of each primer (*APOL1* 319_1F: 5'-CAGCATCCTGGAAATGAGC-3'; *APOL1* 319_1R: 5'-GCCCTGTGGTCACAGTTCTT-3') and 1 unit of Taq polymerase (MP Biomedical, CA, USA). The PCR conditions were: 95°C for 5 min followed by 35 cycles at 95°C for 30 s, 59°C for 30 s, 72°C for 45 s and one cycle of extension, 72°C for 5 min. The PCR products were then digested by fast digest HindIII (ThermoFisher Scientific) and digested fragments separated on 2% agarose gel electrophoresis. The G1^I384M^ (rs60910145) polymorphism was genotyped by the Genome and Transcriptome Platform of Bordeaux using the Sequenom MassArray iplex method. Genotypes were identified with the MassARRay Typer 4.0 Analyzer software. The G2 (rs71785313) indel was detected on a Li-Cor sequencer. The PCR primers were the same as for G1^S342G^ (rs73885319) but the forward primer had a M13 tail (M13 = 5'-CACGACGTTGTAAAACGAC-3'). PCRs were carried out in a total volume of 20 µL containing 25 ng of DNA, 10 mM of dNTP, 10 µM of each primer, 10 mM of dye (M13IR700) and 1 unit of Taq polymerase (MP Biomedical). The PCR conditions were: 95°C for 5 min followed by 35 cycles at 95°C for 30 s, 59°C for 30 s, 72°C for 45 s and one cycle of extension, 72°C for 5 min. The PCR products were then visualized on the Li-Core sequencer for the G2 indel detection. Data for each SNP (rs73885319, rs60910145, and rs71785313) were combined to generate the *APOL1* genotype for each individual.

Statistical analyses {#s4-4}
--------------------

Statistical analyses of association between *APOL1* genotypes and human African trypanosomiasis in this case-control study were performed by contingency table analyses using Fisher's exact test with mid-P method. Statistical tests were computed using Open-epi. Calculation of the minimum detectable odds ratios was performed for the study sample size in Uganda (\<0.144, \>2.662 \[G1\], \< 0.350, \>2.116 \[G2\]) and Guinea (\<0.448, \>2.008 \[G1\], \<0.471, \>1.971\[G2\]) using Sampsize software with the parameters of 80% power, 5% alpha risk and a two-sided test.

Spatial frequency map of G1 and G2 allele frequency and human African trypanosomiasis distribution {#s4-5}
--------------------------------------------------------------------------------------------------

To visualize the geographical distribution of *APOL1* G1 and G2 polymorphisms in sub-Saharan Africa, a contour map was generated by collating data from this study with previously published datasets to produce a cohort of 5287 individuals from across 40 African populations. Published datasets with a low sample size (n ≤ 19) were excluded. G1^S342G^ (rs73885319) was used as a proxy for G1, where G1 frequency data were unavailable (rs73885319 and rs60910145 are in almost complete positive linkage disequilibrium) ([@bib18]; [@bib36]). The contour map was drawn using Surfer 8.0 (Golden Software Inc., Golden, Colorado) applying the Kriging algorithm for data interpolation. Interpolation may be inaccurate where there are few data points. G1 and G2 allele frequencies were analysed for an association with the geographical coordinates (absolute latitude and longitude) using Pearson\'s correlation test (GraphPad Prism version 6.0, RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)). The map of *T.b. rhodesiense* and *T.b. gambiense* endemicity was drawn from the Human African trypanosomiasis endemicity classification of the Global Health Observatory data repository ([@bib67])
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###### Sequence variants identified in protein-coding exons of the *APOL1* gene in *T.b.r* cases and controls.

Sequence variants relative to human genome reference (NCBI Genome browser build 38, RRID:[SCR_006553](https://scicrunch.org/resolver/SCR_006553)) were identified in exon sequences of individuals identified with a G1 or G2 genotype, and a representative number of G0 individuals. S: synonymous SNP, NS: non-synonymous SNP, *T.b.r: T.b. rhodesiense.* The chromosome 22 position is indicated based on NCBI Genome reference build 38.7 and reference SNP ID if present, is indicated as described by dbSNP (RRID:[SCR_002338](https://scicrunch.org/resolver/SCR_002338)). The SNP genotype of each individual is described by the appropriate IUPAC nucleotide code. Rs71785313 (G2) genotypes are described by the presence (TTATAA) or absence (del6) of the six base-pair sequence that is deleted in the G2 variant. Due to limited sample availability, sequence data could not be obtained for two G0/G2 individuals (LIL039 and CT059).

**DOI:** [http://dx.doi.org/10.7554/eLife.25461.018](10.7554/eLife.25461.018)

10.7554/eLife.25461.019

###### Primer information for PCR amplification and sequencing of *APOL1* protein-coding exons

**DOI:** [http://dx.doi.org/10.7554/eLife.25461.019](10.7554/eLife.25461.019)
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Decision letter

Tishkoff

Sarah

Reviewing editor

University of Pennsylvania

,

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"*APOL1* renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis\" for consideration by *eLife*. Your article has been favorably evaluated by Mark McCarthy (Senior Editor) and three reviewers, one of whom, Sarah Tishkoff (Reviewer \#1), is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The authors have conducted a case control study of symptomatic/asymptomatic individuals infected by *T.b. rhodesiense* or by *T.b. gambiense* and association with G1 and G2 variants at *APOL1* that have been implicated in increased risk for kidney disease. This study is of considerable interest and impact because the distribution of these variants in Africa, and their possible adaptive significance, has remained an enigma. They are most common in a subset of West African populations and were previously thought to play a role in resistance only to *T.b. rhodesiense* which is common only in East Africa. In this study, they have demonstrated a protective association for G2 against *T.b. rhodesiense* infection. They also observe opposing associations with T.b. gambiense disease outcome-G1 is associated with asymptomatic infection whereas G2 is associated with faster progression of trypanosomiasis. Overall, the study represents a unique and important addition and clarification to the burgeoning scientific and medical research literature on *APOL1* in relation to infectious disease and in relation to kidney disease risk

Essential revisions:

1\) For all three tables, the summary information (number and percentage of samples) presents the G1 or G2 genotype. It is not clear if this refers to heterozygotes, such that all those listed as G1 are actually genotype G1/G0, and all of those under G2 are G2/G0 genotype, or whether there are homozygotes or compound heterozygotes included. If the latter it is not the case, it would be important to specify this or use more accurate terminology.

2\) The authors seem to have incorrectly added up the amount of G1 *T.b. gambiense* carriers in [Table 3](#tbl3){ref-type="table"}. In the raw data, there are 31 people that fit this category, not 30. The authors have either excluded one of either the G1M/G1 or G1G/G1 individuals but not the other with no provided reasoning, or they have simply missed one when calculating. As written in the first paragraph of the subsection "*APOL1* variants and resistance/susceptibility to *T.b. rhodesiense*" \"partial G1 were excluded\". This should be clarified.

3\) Correct annotation in [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}. For example, sample Bo443-6 in [Table 2](#tbl2){ref-type="table"}\'s raw data is listed as a G1G/G0 despite harboring the del6 at the G2 polymorphism locus. There are five instances of these types of miss annotation between [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}.

4\) Check the calculation for the odds ratio for the tables. We have re calculated all of the odds ratios in each of the tables and both the confidence interval and p value of the G2 odds ratio in [Table 3](#tbl3){ref-type="table"} appears incorrect. We calculate p = 0.0043.

5\) Address the possibility that inactivating mutations have abrogated the trypanolytic effect of either or both of the variants, specifically in regard to the small number of (6) of T.b.r. infected G2 genotype individuals, or the 9 T.b.r. infected G1 genotype individuals. The cleanest way to address this would be to sequence through at least the exomes, and if not, to at least add a sentence addressing the extent of implausibility of this scenario. This issue is less relevant for the results summarized in [Table 2](#tbl2){ref-type="table"} and [Table 3](#tbl3){ref-type="table"}, since opposing robust associations were found.

6\) Include a metric for the odds ratio for the G0 genotype in each of the data tables for comparison to the G1 and G2 genotypes. Secondly, there is some interesting information that is not addressed, such as the fact that the *T.b. gambiense* disease/carriage ratio for people with exclusively the G2/G0 heterozygous genotype is actually 5.008 with a significant p value of 0.0032. Why are these conditional odds ratios not discussed?

7\) Please explain in the body of the text why the compound heterozygotes (G1/G2 genotypes) are not being excluded from these analyses, but rather those individuals are being counted for both the G1 and G2 data sets. If G1 is protective, while G2 exacerbates progression of *T. b. gambiense*, then including compound HETs makes very little sense and the reasoning behind their inclusion should be explained.

8\) Provide more evidence for the hypothesis that *T.b. gambiense* originated in humans from a species jump and tighten up that discussion so that it is less speculative.

9\) Make sure that data source files are accessible.

10\) Add an in vitro killing graph with recombinant proteins of all three genotypes to against *T. b. gambiense* and *T.b. rhodesiense* that can be included to show the in vitro effect.

10.7554/eLife.25461.022

Author response

*Essential revisions:*

*1) For all three tables, the summary information (number and percentage of samples) presents the G1 or G2 genotype. It is not clear if this refers to heterozygotes, such that all those listed as G1 are actually genotype G1/G0, and all of those under G2 are G2/G0 genotype, or whether there are homozygotes or compound heterozygotes included. If the latter it is not the case, it would be important to specify this or use more accurate terminology.*

For all tables, analysis was performed using a dominance model, in which we counted every individual carrying at least one copy of the APOL1 haplotype under analysis (G0, G1 or G2). For example, for the G1 variant, this includes homozygotes (G1/G1), heterozygotes (G1/G0) and compound heterozygotes (G1/G2). We have changed the tables so that exact numbers and percentages both with and without each haplotype are given and added a clarification that this association analysis was performed using a dominant model to each table legend.

Where individuals have been excluded from a particular analysis, for example, individuals with only a partial G1 haplotype have been excluded from the G1 association analysis, this has been detailed in the table legends and in the text (subsection "*APOL1* variants and resistance/susceptibility to *T.b. rhodesiense*", first paragraph).

We have also made the data for the two component SNPs of the G1 haplotype (rs73885319 and rs60910145) available in the source data (source data 2 for each table) so that the association analysis can be accessed for each SNP individually, in addition to the complete G1 haplotype in the main manuscript.

A separate analysis excluding compound heterozygotes (as suggested by the reviewers in a later comment) has also now been included for *T.b. gambiense* infection outcome ([Table 4](#tbl4){ref-type="table"}) and more details of this are given in revision point 7.

*2) The authors seem to have incorrectly added up the amount of G1 T.b. gambiense carriers in [Table 3](#tbl3){ref-type="table"}. In the raw data, there are 31 people that fit this category, not 30. The authors have either excluded one of either the G1M/G1 or G1G/G1 individuals but not the other with no provided reasoning, or they have simply missed one when calculating. As written in the first paragraph of the subsection "APOL1 variants and resistance/susceptibility to T.b. rhodesiense" \"partial G1 were excluded\". This should be clarified.*

A small number of individuals were identified to carry a partial G1 haplotype (the kidney disease risk genotype at one of the G1 polymorphism positions but the non-risk genotype at the other). Individuals possessing only a partial G1 genotype and no full G1 alleles (e.g. G1^G^/G0 or G1^M^/G0) have been excluded from the association analysis of the G1 haplotype. There are 30 individuals that possess the complete G1 haplotype in the *T.b. gambiense* carrier group in [Table 3](#tbl3){ref-type="table"}. Examining the source data we can see that one individual carrying the G1^M^/G0 genotype (and thus excluded) was incorrectly labelled as G1^M^/G1 in the "designated APOL1 genotype" column of [Table 3---source data 1](#SD5-data){ref-type="supplementary-material"}. This was an annotation error and did not affect the statistical calculations. We are grateful to the reviewers for spotting this error and it has now been corrected.

*3) Correct annotation in [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}. For example, sample Bo443-6 in [Table 2](#tbl2){ref-type="table"}\'s raw data is listed as a G1G/G0 despite harboring the del6 at the G2 polymorphism locus. There are five instances of these types of miss annotation between [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}.*

As noted for revision point 2, these were unfortunate annotation errors that were restricted to the source data tables and did not affect any of the statistical calculations. We are grateful to the reviewers for spotting this and they have now been corrected.

*4) Check the calculation for the odds ratio for the tables. We have re calculated all of the odds ratios in each of the tables and both the confidence interval and p value of the G2 odds ratio in [Table 3](#tbl3){ref-type="table"} appears incorrect. We calculate p = 0.0043.*

We have recalculated the odds ratio for G2 in [Table 3](#tbl3){ref-type="table"} using a Two-tailed Fisher\'s exact test with mid-P method and obtained the same odds ratio (3.08) and P value (0.0025) as described in the manuscript. This was calculated using openepi (www.openepi.com) using the numbers provided in [Table 3](#tbl3){ref-type="table"}. A screenshot of our statistical analysis is presented in [Author response image 1](#fig3){ref-type="fig"}.10.7554/eLife.25461.020Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.25461.020](10.7554/eLife.25461.020)

*5) Address the possibility that inactivating mutations have abrogated the trypanolytic effect of either or both of the variants, specifically in regard to the small number of (6) of T.b.r. infected G2 genotype individuals, or the 9 T.b.r. infected G1 genotype individuals. The cleanest way to address this would be to sequence through at least the exomes, and if not, to at least add a sentence addressing the extent of implausibility of this scenario. This issue is less relevant for the results summarized in [Table 2](#tbl2){ref-type="table"} and [Table 3](#tbl3){ref-type="table"}, since opposing robust associations were found.*

For the *T.b. rhodesiense* study ([Table 1](#tbl1){ref-type="table"}), to confirm genotypes the *APOL1* protein-coding exons 3-7 were sequenced from all G1 or G2 positive individuals (with the exception of 2 individuals \[CT059 and LIL039\] for which the availability of sample DNA was limited) and a representative number (16) of G0 individuals. This has now been clarified in the Materials and methods section (subsection "Uganda", last paragraph) and the primer sequences provided in [Supplementary file 2](#SD11-data){ref-type="supplementary-material"}. No stop codons were identified in any individual, although a small number of non-synonymous variants were detected. The sequence data with all identified genetic variants has now been included in [Supplementary file 1](#SD10-data){ref-type="supplementary-material"}. A sentence addressing this issue and the possibility of inactivating mutations or gene dosage has now been included in the text (Discussion, third paragraph).

*6) Include a metric for the odds ratio for the G0 genotype in each of the data tables for comparison to the G1 and G2 genotypes. Secondly, there is some interesting information that is not addressed, such as the fact that the T.b. gambiense disease/carriage ratio for people with exclusively the G2/G0 heterozygous genotype is actually 5.008 with a significant p value of 0.0032. Why are these conditional odds ratios not discussed?*

*7) Please explain in the body of the text why the compound heterozygotes (G1/G2 genotypes) are not being excluded from these analyses, but rather those individuals are being counted for both the G1 and G2 data sets. If G1 is protective, while G2 exacerbates progression of T. b. gambiense, then including compound HETs makes very little sense and the reasoning behind their inclusion should be explained.*

There is no association for either *T.b. rhodesiense* or *T.b. gambiense* with the G0 genotype. This data has now been included in [Tables 1](#tbl1){ref-type="table"}--[3](#tbl3){ref-type="table"} for comparison with the G1 and G2 association analyses.

The reviewers raise an interesting point regarding the strong conditional association for the G2 variant with *T.b. gambiense* disease progression. The opposing associations of G1 and G2 were previously unpredicted for *T.b. gambiense.* In light of their identification in this study and the reviewers comments we have now added extra analyses (presented in [Table 4](#tbl4){ref-type="table"}) to show the association of the G1 and G2 haplotypes with *T.b. gambiense* disease outcome when compound heterozygotes (G1/G2) are excluded. This analysis strengthens the association of G2 with progression of symptomatic *T.b. gambiense* disease from OR 3.08 \[95% CI:1.45 to 7.06\], *P* = 0.0025 to OR 5.87 \[95% CI: 2.16 to 20.01\], *P* =0.0001, suggesting a possible dominance for the protective mechanism of the G1 variant in G1/G2 compound heterozygotes. This data and a brief discussion of its implications has now been added to the text (subsection "Disease outcome", first paragraph; Discussion, fourth paragraph).

*8) Provide more evidence for the hypothesis that T.b. gambiense originated in humans from a species jump and tighten up that discussion so that it is less speculative.*

In the original manuscript we only referred briefly to the evidence supporting the origin of the human-infective subspecies *T.b. rhodesiense* and *T.b. gambiense* from animal-infective *T.b. brucei*. Both of these subspecies possess a different mechanism of human serum resistance and are suggested to have arisen independently and relatively recently from non-human infective *T.b. brucei*. We have now added references that support this hypothesis for both subspecies, based on population genetics and genomics studies (Tait et al.1985, Gibson et al. 2002, Balmer et al. 2011, Weir et al. 2016). We have also referenced a review by Wolfe et al. (2007) published in Nature that discusses the evolutionary origin and intermediate stages of adaptation of many human--infective pathogens from their animal-infective predecessors, including both of the human-infective *T. brucei* subspecies (Discussion, seventh paragraph).

*9) Make sure that data source files are accessible.*

All the source data files for [Tables 1](#tbl1){ref-type="table"}--[4](#tbl4){ref-type="table"} have currently been formatted as excel (xlsx) files but we would be happy to adapt these to any alternative format, as required.

*10) Add an in vitro killing graph with recombinant proteins of all three genotypes to against T. b. gambiense and T.b. rhodesiense that can be included to show the in vitro effect.*

This data has been previously published by others (Genovese et al. 2010) and has been referenced in this manuscript. We have changed the text to clarify that both serum and recombinant protein have been previously tested in in vitro assays (Discussion, second, third and fourth paragraphs).

[^1]: These authors contributed equally to this work.

[^2]: \*Two-tailed Fisher\'s exact test with mid-P method using a dominant genetic model (carriage of 1 or 2 copies of the designated *APOL1* haplotype),.

[^3]: ^†^Individuals with only a partial G1 haplotype were excluded from the analysis. *T.b.r: T.b. rhodesiense*, OR: odds ratio, CI: confidence interval, N.C: not calculable. All raw data for [Table 1](#tbl1){ref-type="table"} can be found in [Table 1---source data 1](#SD1-data){ref-type="supplementary-material"}. The association analysis of the two individual component SNPs of the G1 haplotype can be found in [Table 1---source data 2](#SD2-data){ref-type="supplementary-material"}.

[^4]: ^\*^Two-tailed Fisher\'s exact test with mid-P method using a dominant genetic model (carriage of 1 or 2 copies of the designated *APOL1* haplotype),.

[^5]: ^†^Individuals with a partial G1 haplotype were excluded from the analysis. *T.b.g: T.b. gambiense*, OR: odds ratio, CI: confidence interval. All raw data for [Table 2](#tbl2){ref-type="table"} can be found in [Table 2---source data 1](#SD3-data){ref-type="supplementary-material"}. The association analysis of the two individual component SNPs of the G1 haplotype can be found in [Table 2---source data 2](#SD4-data){ref-type="supplementary-material"}.

[^6]: ^\*^Two-tailed Fisher\'s exact test with mid-P method using a dominant genetic model (carriage of 1 or 2 copies of the designated *APOL1* haplotype),.

[^7]: ^†^Individuals with a partial G1 haplotype were excluded from the analysis. *T.b.g: T.b. gambiense*, OR: odds ratio, CI: confidence interval. Raw data for [Table 3](#tbl3){ref-type="table"} can be found in [Table 3---source data 1](#SD5-data){ref-type="supplementary-material"}. An association analysis of the two individual component SNPs of the G1 haplotype can be found in [Table 3---source data 2](#SD6-data){ref-type="supplementary-material"}.

[^8]: ^\*^Two-tailed Fisher\'s exact test with mid-P method using a dominant model (carriage of 1 or 2 copies of the designated *APOL1* haplotype),.

[^9]: ^†^Individuals with a partial G1 haplotype were excluded from the analysis.

[^10]: ^‡^Individuals with a compound heterozygote genotype (G1/G2) were excluded from the analysis. *T.b.g: T.b. gambiense*, OR: odds ratio, CI: confidence interval. Raw data for [Table 4](#tbl4){ref-type="table"} can be found in [Table 4---source data 1](#SD7-data){ref-type="supplementary-material"}. An association analysis of the two individual component SNPs of the G1 haplotype can be found in [Table 4---source data 2](#SD8-data){ref-type="supplementary-material"}.
